+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Digital Therapeutics Market by Application, Product Type, and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 322 Pages
  • November 2021
  • Region: Global
  • Allied Market Research
  • ID: 5214862
UP TO OFF until Oct 24th 2024
The global digital therapeutics market was valued at $3,537.29 million in 2020, and is projected to reach $23,569.38 million by 2030, registering a CAGR of 20.6% from 2021 to 2030.



Digital therapeutics provides evidence-based therapeutic interventions to patients. It is delivered through software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. The design, clinical validation, usability, and data security of digital therapeutics products are all based on advanced technology best practices. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.

Increase in adoption of smartphones and tablets, coupled with healthcare apps, growth in need to control healthcare cost, significant benefits to the entire healthcare continuum and rise in incidences of chronic diseases drive growth of the global digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.6% from 2021 to 2030. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future. Furthermore, a strong pipeline of potential products that are expected to be launched during the forecast period also provide lucrative opportunities in the future.

The digital therapeutics market is segmented on the basis of application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include 2MORROW, Inc., Akili Interactive Labs, Inc., Click Therapeutics, Inc., Fitbit, Inc. (Twine Health, Inc.), Happify, Inc., Kaia Health, Livongo Health, Inc., Medtronic Plc., Omada Health, Inc., Pear Therapeutics, Inc., Proteus Digital Health, Inc., Resmed, Inc. (Propeller Health), Voluntis, Inc., Welldoc, Inc. Other players operating in the digital therapeutics market include GlaxoSmithKline, Mango Health Inc., Veeva Systems, Healthmine Inc., Blue Mesa, Virta Health Corp, Glooko Inc., and among others.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global digital therapeutics.

KEY MARKET SEGMENTS


By application

  • Diabetes
  • Obesity
  • Cardiovascular Disease (CVD)
  • Central Nervous System (CNS) Disease
  • Respiratory Disease
  • Smoking Cessation
  • Gastrointestinal Disorder (GID)
  • Others

By Product Type

  • Software
  • Device

By Sales Channel

  • Business-to-Business (B2B)
  • Employer
  • Healthcare Provider
  • Others
  • Business-to-Consumer (B2C)
  • Patient
  • Caregiver

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Turkey
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • 2MORROW, Inc.
  • Akili Interactive Labs, Inc.
  • Click Therapeutics, Inc.
  • Fitbit, Inc. (Twine Health, Inc.)
  • Happify, Inc.
  • Kaia Health
  • Livongo Health, Inc.
  • Medtronic Plc.
  • Omada Health, Inc.
  • Pear Therapeutics, Inc.
  • Proteus Digital Health, Inc.
  • Resmed, Inc. (Propeller Health)
  • Voluntis, Inc.
  • Welldoc, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Lark Health
  • Akili Interactive
  • One Drop

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key Market Segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2020
3.4. Porter’s five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in adoption of smartphones and tablets, coupled with healthcare apps
3.5.1.2. Rise in need to control healthcare costs
3.5.1.3. Rise in incidences of chronic diseases
3.5.1.4. Significant benefits to the entire healthcare continuum
3.5.2. Restraints
3.5.2.1. Lack of awareness regarding digital therapeutics in developing countries
3.5.2.2. Patient data privacy concerns
3.5.3. Opportunity
3.5.3.1. Extensive product pipeline
3.6. Impact analysis of COVID-19 on the digital therapeutics market
3.7. Impact of government regulations on global digital therapeutics market
3.7.1. U.S. FDA’s premarket clearance and approval requirements
3.7.2. European Union premarket clearance and approval requirements
3.7.3. Japan premarket clearance and approval requirements
3.8. Strategy adopted by top 10 start-ups
3.8.1. Meru Health, Inc.
3.8.2. Bold Health Limited
3.8.3. BehaVR, LLC
3.8.4. Naluri Hidup Sdn Bhd
3.8.5. Big Health
3.8.6. Hinge Health, Inc.
3.8.7. Glooko, Inc.
3.8.8. Holmusk Pte. Ltd.
3.8.9. Wellthy Therapeutics Pvt Ltd.
3.8.10. Virta Health Corp.
3.9. Key digital technologies for digital therapeutics
3.9.1. Mobile health (mHealth)
3.9.2. Personalized healthcare
3.9.3. Digital Cognitive Behavior Therapy (CBT)
3.9.4. Wearable devices and sensors
3.10. Necessary human resources required for digital therapeutics development
3.11. Usage of patient data acquired from digital therapeutics
3.11.1. Types of personal information that are collected by DTx companies
CHAPTER 4: DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Diabetes
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Obesity
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Cardiovascular diseases
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Central nervous system (CNS) diseases
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Gastrointestinal disorder
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Respiratory diseases
4.7.1. Key market trends and growth opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
4.8. Smoking cessation
4.8.1. Key market trends and growth opportunities
4.8.2. Market size and forecast
4.8.3. Market analysis, by country
4.9. Others
4.9.1. Key market trends and growth opportunities
4.9.2. Market size and forecast
4.9.3. Market analysis, by country
CHAPTER 5: DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1. Overview
5.1.1. Market size and forecast
5.2. Software
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Devices
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
CHAPTER 6: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Business-to-business (B2B)
6.2.1. Market size and forecast, by type
6.2.1.1. Employer
6.2.1.1.1. Market size and forecast
6.2.1.2. Healthcare Providers
6.2.1.2.1. Market size and forecast
6.2.1.3. Others
6.2.1.3.1. Market size and forecast
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. Business-to-consumers
6.3.1. Market size and forecast, by type
6.3.1.1. Patients
6.3.1.1.1. Market size and forecast
6.3.1.2. Caregivers
6.3.1.2.1. Market size and forecast
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
CHAPTER 7: DIGITAL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America digital therapeutics market, by country
7.2.3. North America digital therapeutics market, by application
7.2.4. North America digital therapeutics market, by product type
7.2.5. North America digital therapeutics market, by sales channel
7.2.5.1. U.S.
7.2.5.1.1. U.S. digital therapeutics market, by application
7.2.5.1.2. U.S digital therapeutics market, by product type
7.2.5.1.3. U.S. digital therapeutics market, by sales channel
7.2.5.2. Canada
7.2.5.2.1. Canada digital therapeutics market, by application
7.2.5.2.2. Canada digital therapeutics market, by product type
7.2.5.2.3. Canada digital therapeutics market, by sales channel
7.2.5.3. Mexico.
7.2.5.3.1. Mexico digital therapeutics market, by application
7.2.5.3.2. Mexico digital therapeutics market, by product type
7.2.5.3.3. Mexico digital therapeutics market, by sales channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe digital therapeutics market, by country
7.3.3. Europe digital therapeutics market, by application
7.3.4. Europe digital therapeutics market, by product type
7.3.5. Europe digital therapeutics market, by sales channel
7.3.5.1. U.K
7.3.5.1.1. UK digital therapeutics market, by application
7.3.5.1.2. UK digital therapeutics market, by product type
7.3.5.1.3. UK digital therapeutics market, by sales channel
7.3.5.2. Germany.
7.3.5.2.1. Germany digital therapeutics market, by application
7.3.5.2.2. Germany digital therapeutics market, by product type
7.3.5.2.3. Germany digital therapeutics market, by sales channel
7.3.5.3. France.
7.3.5.3.1. France digital therapeutics market, by application
7.3.5.3.2. France digital therapeutics market, by product type
7.3.5.3.3. France digital therapeutics market, by sales channel
7.3.5.4. Italy
7.3.5.4.1. Italy digital therapeutics market, by application
7.3.5.4.2. Italy digital therapeutics market, by product type
7.3.5.4.3. Italy digital therapeutics market, by sales channel
7.3.5.5. Spain
7.3.5.5.1. Spain digital therapeutics market, by application
7.3.5.5.2. Spain digital therapeutics market, by product type
7.3.5.5.3. Spain digital therapeutics market, by sales channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Rest of Europe digital therapeutics market, by application
7.3.5.6.2. Rest of Europe digital therapeutics market, by product type
7.3.5.6.3. Rest of Europe digital therapeutics market, by sales channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific digital therapeutics market, by country
7.4.3. Asia-Pacific digital therapeutics market, by application
7.4.4. Asia-Pacific digital therapeutics market, by product type
7.4.5. Asia-Pacific digital therapeutics market, by sales channel
7.4.5.1. Japan
7.4.5.1.1. Japan digital therapeutics market, by application
7.4.5.1.2. Japan digital therapeutics market, by product type
7.4.5.1.3. Japan digital therapeutics market, by sales channel
7.4.5.2. China
7.4.5.2.1. China digital therapeutics market, by application
7.4.5.2.2. China digital therapeutics market, by product type
7.4.5.2.3. China digital therapeutics market, by sales channel
7.4.5.3. Australia
7.4.5.3.1. Australia digital therapeutics market, by application
7.4.5.3.2. Australia digital therapeutics market, by product type
7.4.5.3.3. Australia digital therapeutics market, by sales channel
7.4.5.4. India
7.4.5.4.1. India digital therapeutics market, by application
7.4.5.4.2. India digital therapeutics market, by product type
7.4.5.4.3. India digital therapeutics market, by sales channel
7.4.5.5. South Korea
7.4.5.5.1. South Korea digital therapeutics market, by application
7.4.5.5.2. South Korea digital therapeutics market, by product type
7.4.5.5.3. South Korea digital therapeutics market, by sales channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Rest of Asia-Pacific digital therapeutics market, by application
7.4.5.6.2. Rest of Asia-Pacific digital therapeutics market, by product type
7.4.5.6.3. Rest of Asia-Pacific digital therapeutics market, by sales channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA digital therapeutics market, by country
7.5.3. LAMEA digital therapeutics market, by application
7.5.4. LAMEA digital therapeutics market, by product type
7.5.5. LAMEA digital therapeutics market, by sales channel
7.5.5.1. Brazil
7.5.5.1.1. Brazil digital therapeutics market, by application
7.5.5.1.2. Brazil digital therapeutics market, by product type
7.5.5.1.3. Brazil digital therapeutics market, by sales channel
7.5.5.2. Turkey
7.5.5.2.1. Turkey digital therapeutics market, by application
7.5.5.2.2. Turkey digital therapeutics market, by product type
7.5.5.2.3. Turkey digital therapeutics market, by sales channel
7.5.5.3. Saudi Arabia
7.5.5.3.1. Saudi Arabia digital therapeutics market, by application
7.5.5.3.2. Saudi Arabia digital therapeutics market, by product type
7.5.5.3.3. Saudi Arabia digital therapeutics market, by sales channel
7.5.5.4. South Africa
7.5.5.4.1. South Africa digital therapeutics market, by application
7.5.5.4.2. South Africa digital therapeutics market, by product type
7.5.5.4.3. South Africa digital therapeutics market, by sales channel
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Rest of LAMEA digital therapeutics market, by application
7.5.5.5.2. Rest of LAMEA digital therapeutics market, by product type
7.5.5.5.3. Rest of LAMEA digital therapeutics market, by sales channel
CHAPTER 8: COMPANY PROFILES
8.1.2MORROW, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Key strategic moves and developments
8.2. AKILI INTERACTIVE LABS, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio
8.2.4. Key strategic moves and developments
8.3. CLICK THERAPEUTICS, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments
8.4. FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. HAPPIFY, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product portfolio
8.5.4. Key strategic moves and developments
8.6. KAIA HEALTH
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.6.4. Key strategic moves and developments
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. OMADA HEALTH, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. PEAR THERAPEUTICS, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Key strategic moves and developments
8.10. PROTEUS DIGITAL HEALTH, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Key strategic moves and developments
8.11. RESMED, INC. (PROPELLER HEALTH)
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Business performance
8.11.6. Key strategic moves and developments
8.12. TELADOC HEALTH, INC.(LIVONGO HEALTH)
8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Product portfolio
8.12.4. Business performance
8.12.5. Key strategic moves and developments
8.13. VOLUNTIS, INC.
8.13.1. Company overview
8.13.2. Company snapshot
8.13.3. Operating business segments
8.13.4. Product portfolio
8.13.5. Business performance
8.13.6. Key strategic moves and developments
8.14. WELLDOC, INC.
8.14.1. Company overview
8.14.2. Company snapshot
8.14.3. Operating business segments
8.14.4. Product portfolio
8.14.5. Key strategic moves and developments
List of Tables
TABLE 01. DIGITAL THERAPEUTIC PRODUCT LIST
TABLE 02. FDA CLASSIFICATION OF MEDICAL DEVICES
TABLE 03. DIGITAL SKILLS REQUIRED FOR EMPLOYEES DEDICATED FOR DTX DEVELOPMENTS
TABLE 04. RANGE OF NUMBER OF EMPLOYEES WITH DIGITAL SKILLS DEDICATED FOR DIGITAL THERAPEUTICS DEVELOPMENTS, BY COMPANY
TABLE 05. GLOBAL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 06. DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2020-2030 ($MILLION)
TABLE 07. DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2020-2030 ($MILLION)
TABLE 08. DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2030 ($MILLION)
TABLE 09. DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 10. SMART PILLS FOR CAPSULE ENDOSCOPY, DRUG DELIVERY, AND PATIENT MONITORING AVAILABLE IN THE MARKET
TABLE 11. DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY REGION, 2020-2030 ($MILLION)
TABLE 12. DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 13. DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2020-2030 ($MILLION)
TABLE 14. DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 15. GLOBAL DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 16. DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 17. GLOBAL DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
TABLE 18. GLOBAL DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY REGION, 2020-2030 ($MILLION)
TABLE 19. GLOBAL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2030 ($MILLION)
TABLE 20. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2020-2030 ($MILLION)
TABLE 21. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY REGION, 2020-2030 ($MILLION)
TABLE 22. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2020-2030 ($MILLION)
TABLE 23. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY REGION, 2020-2030 ($MILLION)
TABLE 24. DIGITAL THERAPEUTICS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 25. NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 26. NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27. NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 28. NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 29. U.S. DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30. U.S. DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 31. U.S. DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2030 ($MILLION)
TABLE 32. CANADA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 33. CANADA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 34. CANADA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 35. MEXICO DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 36. MEXICO DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 37. MEXICO DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 38. EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 39. EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40. EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 41. EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 42. UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43. UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 44. UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 45. GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46. GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 47. GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 48. FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 49. FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 50. FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 51. ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 52. ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 53. ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 54. SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 55. SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 56. SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 57. REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 58. REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 59. REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 60. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 61. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 62. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 63. ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 64. JAPAN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 65. JAPAN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 66. JAPAN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 67. CHINA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 68. CHINA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 69. CHINA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 70. AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 71. AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 72. AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 73. INDIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 74. INDIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 75. INDIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 76. SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 77. SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 78. SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 82. LAMEA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 83. LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 84. LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 85. LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 86. BRAZIL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 87. BRAZIL DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 88. BRAZIL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 89. TURKEY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 90. TURKEY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 91. TURKEY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 92. SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 93. SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 94. SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 95. SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 96. SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 97. SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 98. REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 99. REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2020–2030 ($MILLION)
TABLE 100. REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2030 ($MILLION)
TABLE 101.2MORROW: COMPANY SNAPSHOT
TABLE 102.2MORROW: PRODUCT PORTFOLIO
TABLE 103. AKILI: COMPANY SNAPSHOT
TABLE 104. AKILI: PRODUCT PORTFOLIO
TABLE 105. CLICK THERAPEUTICS: COMPANY SNAPSHOT
TABLE 106. CLICK THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 107. FITBIT: COMPANY SNAPSHOT
TABLE 108. FITBIT: PRODUCT PORTFOLIO
TABLE 109. HAPPIFY: COMPANY SNAPSHOT
TABLE 110. HAPPIFY: PRODUCT PORTFOLIO
TABLE 111. KAIA: COMPANY SNAPSHOT
TABLE 112. KAIA: PRODUCT PORTFOLIO
TABLE 113. MEDTRONIC: COMPANY SNAPSHOT
TABLE 114. MEDTRONIC: OPERATING SEGMENTS
TABLE 115. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 116. OMADA: COMPANY SNAPSHOT
TABLE 117. OMADA: PRODUCT PORTFOLIO
TABLE 118. PEAR: COMPANY SNAPSHOT
TABLE 119. PEAR: PRODUCT PORTFOLIO
TABLE 120. PROTEUS: COMPANY SNAPSHOT
TABLE 121. PROTEUS: PRODUCT PORTFOLIO
TABLE 122. RESMED: COMPANY SNAPSHOT
TABLE 123. RESMED: OPERATING SEGMENTS
TABLE 124. RESMED: PRODUCT PORTFOLIO
TABLE 125. TELADOC: COMPANY SNAPSHOT
TABLE 126. TELADOC: PRODUCT PORTFOLIO
TABLE 127. VOLUNTIS: COMPANY SNAPSHOT
TABLE 128. VOLUNTIS: OPERATING SEGMENTS
TABLE 129. VOLUNTIS: PRODUCT PORTFOLIO
TABLE 130. WELLDOC: COMPANY SNAPSHOT
TABLE 131. WELLDOC: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKET IN DIGITAL THERAPEUTICS MARKET, 2020
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018–2021*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018–2021*
FIGURE 06. TOP PLAYER POSITIONING, 2020
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH BARGAINING POWER OF BUYERS
FIGURE 09. LOW THREAT OF SUBSTITUTION
FIGURE 10. MODERATE THREAT OF NEW ENTRANT
FIGURE 11. MODERATE COMPETITIVE RIVALRY
FIGURE 12. GLOBAL DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13. DIGITAL THERAPEUTICS MARKET, BY APPLICATION
FIGURE 14. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2020 & 2030, ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020& 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25. DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 26. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2020-2030 ($MILLION)
FIGURE 27. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2020-2030 ($MILLION)
FIGURE 28. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2020-2030 ($MILLION)
FIGURE 29. COMPARATIVE ANALYSIS OF BUSINESS-TO-BUSINESS MARKET, BY COUNTRY 2020 & 2030 ($MILLION)
FIGURE 30. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2020-2030 ($MILLION)
FIGURE 31. DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2020-2030 ($MILLION)
FIGURE 32. COMPARATIVE ANALYSIS OF BUSINESS-TO-CONSUMERS, BY COUNTRY 2020 & 2030 ($MILLION)
FIGURE 33. U.S. DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 34. CANADA. DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 35. MEXICO DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 36. U.K DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 37. GERMANY DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 38. FRANCE DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 39. ITALY DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 40. SPAIN DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 41. REST OF EUROPE DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 42. JAPAN DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 43. CHINA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 44. AUSTRALIA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 45. INDIA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 46. SOUTH KOREA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 47. REST OF ASIA PACIFIC DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 48. BRAZIL DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 49. TURKEY DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 50. SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 51. SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 52. REST OF LAMEA DIGITAL THERAPEUTICS MARKET, 2020-2030 ($MILLION)
FIGURE 53. FITBIT: NET SALES, 2017–2019 ($MILLION)
FIGURE 54. FITBIT: NET SALES, BY REGION, 2019 (%)
FIGURE 55. MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 56. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 57. MEDTRONIC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 58. RESMED: NET SALES, 2018–2020 ($MILLION)
FIGURE 59. RESMED: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 60. RESMED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 61. TELADOC: NET SALES, 2018–2020 ($MILLION)
FIGURE 62. TELADOC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 63. VOLUNTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 64. VOLUNTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 65. VOLUNTIS: REVENUE SHARE, BY REGION, 2020 (%)

Companies Mentioned

  • 2MORROW Inc.
  • Akili Interactive Labs Inc.
  • Click Therapeutics Inc.
  • Fitbit Inc. (Twine Health Inc.)
  • Happify Inc.
  • Kaia Health Livongo Health Inc.
  • Medtronic Plc.
  • Omada Health Inc.
  • Pear Therapeutics Inc.
  • Proteus Digital Health Inc.
  • Resmed Inc.
  • (Propeller Health) Voluntis Inc.
  • Welldoc Inc.
  • GlaxoSmithKline
  • Mango Health Inc.
  • Veeva Systems
  • Healthmine Inc.
  • Blue Mesa
  • Virta Health Corp
  • Glooko Inc

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information